Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial corticosteroid pulse versus IVIG for Kawasaki disease
IRCT20181202041817N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of methylprednisolone, prednisolone, Human normal immunoglobulin G and aspirin in Kawasaki disease (KD), sponsored by Tehran University of Medical Sciences. Primary endpoints: Fever duration, Frequency of symptoms and 3 more. Started Feb 2019; status: completed.
02
Drugs
methylprednisoloneprednisoloneHuman normal immunoglobulin Gaspirin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on IRCT20181202041817N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181202041817N1.